RadTox™ is a liquid biopsy test that quantifies circulating cell-free DNA (cfDNA) levels in plasma to monitor cancer treatment response and prognosis, using proprietary isobDNA™ technology.

Key advantages include pan-cancer applicability, earlier detection of treatment response than imaging, small sample requirement, cost-effectiveness, and rapid turnaround time.

RadTox™ provides real-time insights into tumor dynamics and treatment response, often earlier than imaging, and complements imaging and tissue biopsies for comprehensive monitoring.

Yes, RadTox™ is a CLIA-certified LDT, and is covered by Medicare and some private insurers starting January 2024.

RadTox™ test is a pan-cancer test suitable for monitoring treatment responses and tumor recurrence across all solid tumor types and stages, without the need for prior tumor genomic profiling.

RadTox™ can be performed as frequently as weekly or biweekly during active treatment, and monthly during surveillance, enabling continuous monitoring.

The RadTox™ test has a rapid turnaround time of approximately 5-7 days, facilitating timely clinical decision-making.

While ctDNA tests provide genomic insights, RadTox™ quantifies total cfDNA levels, offering a complementary perspective on tumor burden and treatment response.

Yes, studies show that baseline cfDNA levels and changes during treatment can be prognostic for outcomes like overall survival and progression-free survival.

RadTox™ can detect significant increases in cfDNA levels that may indicate molecular residual disease (MRD) or tumor recurrence, often earlier than imaging or conventional biomarkers.